

## Impact of ABO-mismatching following HLA-mismatched unrelated donor hematopoietic stem cell transplantation for AML: a report from the ALWP of the EBMT

Bipin N. Savani, Myriam Labopin, Jonathan Canaani, Mauricette Michallet, Charles Craddock, Gerard Socié, Liisa Volin, Johan A. Maertens, Charles Crawley, Didier Blaise, Per T. Ljungman, Jan Cornelissen, Nigel Russell, Frédéric Baron, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Arnon Nagler

### Angaben zur Veröffentlichung / Publication details:

Savani, Bipin N., Myriam Labopin, Jonathan Canaani, Mauricette Michallet, Charles Craddock, Gerard Socié, Liisa Volin, et al. 2017. "Impact of ABO-mismatching following HLA-mismatched unrelated donor hematopoietic stem cell transplantation for AML: a report from the ALWP of the EBMT." *Biology of Blood and Marrow Transplantation* 23 (3): S83. <https://doi.org/10.1016/j.bbmt.2017.01.038>.

## 85

# Impact of ABO-Mismatching Following HLA-Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for AML—a Report From the ALWP of the EBMT

**Bipin N. Savani**<sup>1</sup>, Myriam Labopin<sup>2</sup>, Jonathan Canaani<sup>3</sup>, Mauricette Michallet<sup>4</sup>, Charles Craddock<sup>5</sup>, Gerard Socié<sup>6</sup>, Liisa Volin<sup>7</sup>, Johan A. Maertens<sup>8</sup>, Charles Crawley<sup>9</sup>, Didier Blaise<sup>10</sup>, Per T. Ljungman<sup>11</sup>, Jan Cornelissen<sup>12</sup>, Nigel Russell<sup>13</sup>, Frédéric Baron<sup>14</sup>, Norbert Gorin<sup>2</sup>, Jordi Esteve<sup>15</sup>, Fabio Ciceri<sup>16</sup>, Christoph Schmid<sup>17</sup>, Sebastian Giebel<sup>18</sup>, Mohamad Mohty<sup>19</sup>, Arnon Nagler<sup>20</sup>.

<sup>1</sup> Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; <sup>2</sup> Hopital Saint-Antoine, Paris, France; <sup>3</sup> Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel; <sup>4</sup> Department of Hematology, Hopital Edouard Herriot, CHRU Lyon, Lyon, France; <sup>5</sup> Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom; <sup>6</sup> Saint Louis Hospital, Paris, France; <sup>7</sup> Third Department of Medicine, Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland; <sup>8</sup> Department of Hematology, University Hospitals of Leuven, KU LEUVEN, Leuven, Belgium; <sup>9</sup> Dept of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom; <sup>10</sup> Hematology Department, Institut Paoli Calmettes, Marseille, France; <sup>11</sup> Hematology, Karolinska University Hospital, Stockholm, Sweden; <sup>12</sup> Hematology, Erasmus University Medical Center, Rotterdam, Netherlands; <sup>13</sup> Nottingham City Hospital, Nottingham, United Kingdom; <sup>14</sup> Hematology, University of Liège, GIGA-I3, Liège, Belgium; <sup>15</sup> Hospital Clínic, Hematology department, IDIBAPS, Barcelona, Spain; <sup>16</sup> Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>17</sup> Department of Hematology and Oncology, Klinikum Augsburg, Ludwig-Maximilians-University, Munich, Germany; <sup>18</sup> Department of Bone Marrow Transplantation and Oncohematology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; <sup>19</sup> Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, Paris, France; <sup>20</sup> The Bone Marrow Transplantation Department, Division of Internal Medicine, The Chaim Sheba Medical Center, Tel-Hashomer, Israel

**Background:** ABO incompatibility between donor and recipient is not considered a barrier to successful allogeneic hematopoietic stem cell transplantation (HCT). Nearly one-half of all HCT will involve recipient-donor ABO mismatching (ABO-MM), which can be classified as either major, minor or bidirectional. The analyses of clinical outcomes in ABO-MM HCT have yielded inconsistent results and no large series have studied the impact of ABO-MM in patients (pts) receiving mismatched unrelated donor HCT (MMURD-HCT).

**Methods:** We identified 1013 pts who underwent MMURD-HCT (876 peripheral blood donors, 137 bone marrow [BM] donors) from January 2005 to December 2014 and studied the long term impact of ABO-MM MMURD-HCT in pts with AML. The comparative analysis was performed between pts receiving ABO-matched vs. ABO-MM for common outcome variables. PB and BM groups were analyzed separately.

**Results:** Among the PB group, 349 (40%) pts received ABO-matched grafts whereas 527 (60%) underwent ABO-MM MMURD-HCT including 241 (28%) minor ABO-MM (minor-A, 160 [66%]), 215 (24%) major ABO-MM (major-O, 200 [93%]) and 71 (8%) bidirectional ABO-MM (Bidirectional-A, 37 [52%]). Median age was 53 years (range, 18–75) and was not significantly different between ABO groups ( $P = .27$ ). The median

follow-up period was 34 months (IQR,13–59). More than half of pts were in CR1 and nearly one third of pts were with active disease prior to transplantation. 369 (42%) pts received ablative and 507 (58%) reduced intensity or non-ablative conditioning regimens. The donor graft was HLA-matched at 9/10 in 782 (89%) and at 8/10 in 94 (11%) pts. 785 (90%) pts received either *in vivo* (87%) or *ex vivo* T-cell (3%) depletion. There were no significant differences in distributions of pts and transplant characteristics among ABO- groups. 97% pts engrafted and the rate of engraftment (ABO-matched 97%; major-MM 98%, minor-MM 95%, bidirectional 97%) was not different between ABO-groups ( $P = .32$ ). The cumulative incidences (CI) of day 100 grade II–IV acute GVHD was 30% (III–IV, 13%) and the 3-year CI of chronic GVHD was 37% (95% CI, 33–40), and were not significantly different between the ABO-groups ( $P = .20$  and  $.39$ ). At 3 years, OS, LFS, RI, NRM and GVHD-free/relapse-free survival (GRFS) for the entire cohort were 43%, 38%, 36%, 26% and 29%, respectively. No significant differences in OS, LFS, RI, NRM, GRFS and chronic GVHD were observed between ABO-groups, in multivariate analysis. The analyses were performed separately for pts receiving BM grafts (ABO matched 57; ABO-MM 80 [minor 39, major/ bidirectional 41]). Similarly, there was no statistical difference between ABO-groups for OS, LFS, RI, NRM, GFRS and chronic GVHD.

**Conclusion:** Despite the limitation of a retrospective registry based study, our large series shows no significant long term outcome difference between ABO-matched and mismatched groups after MMURD-HCT in current era.

## 86

# Comparable Survival with Organ Toxicity Predicting for Overall Survival (OS) and Non-Relapse Mortality (NRM) in Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

**Gunjan L. Shah**<sup>1</sup>, Michael Scordo<sup>1</sup>, Satyajit Kosuri<sup>1</sup>, Diego A. Adrianzen Herrera<sup>2</sup>, Christina Cho<sup>1</sup>, Molly Maloy<sup>1</sup>, Jimmy Nieves<sup>3</sup>, Sean M. Devlin<sup>4</sup>, Taylor Borrill<sup>1</sup>, Dean Carlow<sup>5</sup>, Scott T. Avecilla<sup>5</sup>, Richard Meagher<sup>5</sup>, Richard J. O'Reilly<sup>6</sup>, Guenther Koehne<sup>1</sup>, Brian Shaffer<sup>1</sup>, Miguel-Angel Perales<sup>1</sup>, Boglarka Gyurkocza<sup>1</sup>, Hugo Castro-Malaspina<sup>1</sup>, Sergio A. Giral<sup>1</sup>, Roni Tamari<sup>1</sup>.

<sup>1</sup> Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup> Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY; <sup>3</sup> Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>4</sup> Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>5</sup> Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>6</sup> Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

**Introduction:** Ex vivo CD 34+ selection prior to allo-HCT reduces GVHD without increasing relapse, but usually requires myeloablative conditioning. We aimed to identify toxicity patterns in older patients & the association with OS & NRM.

**Methods:** A retrospective analysis was performed at Memorial Sloan Kettering Cancer Center including 200 pts who underwent CD34+ selection allo-HCT using the ClinicMACS® system between 2006–2012. All grade 3–5 toxicities by CTCAE v4.0 were collected and compared between pts  $\geq 60$  or  $<60$  yrs. Individual toxicities were organized into 91 toxicity categories